Loopbaan van Ross G. Clark
Eerdere bekende functies van Ross G. Clark
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Tercica, Inc.
 Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Directeur/Bestuurslid | 01-12-2001 | 21-06-2008 |
| Hoofd Techniek/Wetenschap/O&O | 01-12-2001 | 21-06-2008 | |
| Auckland University | Corporate Officer/Principal | 01-09-1997 | 21-06-2008 |
| NeuronZ Ltd. | Hoofd Techniek/Wetenschap/O&O | 01-10-1997 | 01-01-2000 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Hoofd Techniek/Wetenschap/O&O | 01-01-1990 | 01-01-1997 |
| ViaLactia Biosciences (NZ) Ltd. | Directeur/Bestuurslid | 01-07-1999 | - |
| Tercica Ltd. | Corporate Officer/Principal | 01-09-2000 | - |
Opleiding van Ross G. Clark
| Massey University | Doctorate Degree |
Statistieken
Internationaal
| Nieuw-Zeeland | 6 |
| Verenigde Staten | 3 |
Operationeel
| Chief Tech/Sci/R&D Officer | 3 |
| Director/Board Member | 2 |
| Corporate Officer/Principal | 2 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Health Technology |
| Tercica Ltd. | |
| NeuronZ Ltd. | |
| ViaLactia Biosciences (NZ) Ltd. | |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
- Beurs
- Insiders
- Ross G. Clark
- Ervaring
